Psychopharmacological treatment in pathological gambling: A critical review

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1389-1395

  Achab, Sophia ^a   Khazaal, Yasser ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antidepressant; Carbamazepine; Drugs; Glutamate; Lithium; N acetylcysteine; Nalmefene; Naltrexone; Pathological gambling; Topiramate; Valproate

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; LITHIUM; MEMANTINE; NALMEFENE; NALTREXONE; NEFAZODONE; OLANZAPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

ANXIETY DISORDER; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; GAMBLING; HUMANS; PSYCHOTROPIC DRUGS;

EID: 79959934411     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150774     Document Type: Review

References (52)

1. Bondolfi G, Jermann F, Ferrero F, Zullino D, Osiek C. Prevalence of pathological gambling in Switzerland after the opening of casinos and the introduction of new preventive legislation. Acta psychiatrica Scandinavica 2008; 117(3): 236-9.
2. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in neuro-psychopharmacology & biological psychiatry 2003; 27(1): 85-102.
3. Blanco C, Orensanz-Munoz L, Blanco-Jerez C, Saiz-Ruiz J. Pathological gambling and platelet MAO activity: a psychobiological study. The American journal of psychiatry. 1996; 153(1): 119-21.
4. DeCaria CM, Hollander E, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. The Journal of clinical psychiatry. 1996; 57 Suppl 8: 80-3; discussion 3-4.
5. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. The Journal of clinical psychiatry 2002; 63(1): 44-8.
6. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. International clinical psychopharmacology 2006; 21(4): 203-9.
7. Black DW, Shaw M, Forbush KT, Allen J. An open-label trial of escitalopram in the treatment of pathological gambling. Clinical neuropharmacology 2007; 30(4): 206-12.
8. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. The Journal of clinical psychiatry 2002; 63(11): 1034-9.
9. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebocontrolled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14(1): 9-15.
10. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A doubleblind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. The Journal of clinical psychiatry 2002; 63(6): 501-7.
11. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. International clinical psychopharmacology 2003; 18(4): 243-9.
12. Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: a pilot study. The Journal of clinical psychiatry 2005; 66(1): 28-33.
13. Zwar N, Richmond R. Bupropion sustained release. A therapeutic review of Zyban. Australian family physician 2002; 31(5): 443-7.
14. Black DW. An open-label trial of bupropion in the treatment of pathologic gambling. Journal of clinical psychopharmacology 2004; 24(1): 108-10.
15. Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebocontrolled, flexible-dose study. Journal of clinical psychopharmacology 2007; 27(2): 143-50.
16. Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. Journal of clinical psychopharmacology 2005; 25(6): 593-6.
17. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. The Journal of clinical psychiatry 2002; 63(7): 559-64.
18. McElroy SL, Pope HG, Jr., Keck PE, Jr., Hudson JI, Phillips KA, Strakowski SM. Are impulse-control disorders related to bipolar disorder? Comprehensive psychiatry. 1996; 37(4): 229-40.
19. Black DW, Shaw MC, Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Progress in neuro-psychopharmacology & biological psychiatry 2008; 32(5): 1191-4.
20. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? The American journal of psychiatry 2005; 162(1): 137-45.
21. Hollander E, Buchsbaum MS, Haznedar MM, et al. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism. Neuropsychobiology 2008; 58(1): 37-47.
22. Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. Journal of gambling studies / co-sponsored by the National Council on Problem Gambling and Institute for the Study of Gambling and Commercial Gaming 2003; 19(1): 85-109.
23. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane database of systematic reviews (Online).12: CD001867.
24. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. International clinical psychopharmacology 2001; 16(5): 285-9.
25. Lahti T, Halme JT, Pankakoski M, Sinclair D, Alho H. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacology bulletin. 2010; 43(3): 35-44.
26. Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo- controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions 2009; 18(3): 219-25.
27. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological psychiatry 2001; 49(11): 914-21.
28. Grant JE, Kim SW, Hartman BK. A double-blind, placebocontrolled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. The Journal of clinical psychiatry 2008; 69(5): 783-9.
29. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double- blind, placebo-controlled study. Br J Psychiatry 2010; 197(4): 330-1.
30. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. The American journal of psychiatry 2006; 163(2): 303-12.
31. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE, Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. The Journal of clinical psychiatry 2008; 69(3): 433-40.
32. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double- blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacology, biochemistry, and behavior 2008; 89(3): 298-303.
33. Ma YY, Cepeda C, Cui CL. The role of striatal NMDA receptors in drug addiction. International review of neurobiology 2009; 89: 131-46.
34. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature neuroscience 2003; 6(7): 743-9.
35. Balfour ME, Yu L, Coolen LM. Sexual behavior and sexassociated environmental cues activate the mesolimbic system in male rats. Neuropsychopharmacology 2004; 29(4): 718-30.
36. LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions 2006; 15(1): 105-10.
37. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biological psychiatry 2007 15; 62(6): 652-7.
38. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. Nmethyl- D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & therapeutics 2003; 99(1): 79-94.
39. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology.; 212(4): 603-12.
40. Zullino DF, Krenz S, Zimmerman G, et al. Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/ mianserin. Subst Abus 2005; 25(4): 27-33.
41. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003 May 17; 361(9370): 1677-85.
42. Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry and clinical neurosciences 2006; 60(3): 384-8.
43. Khazaal Y, Zullino DF. Topiramate in the treatment of compulsive sexual behavior: case report. BMC psychiatry 2006; 6: 22.
44. Khazaal Y, Zullino DF. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol 2007; 63(9): 891-2; author reply 3.
45. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biological psychiatry 2007; 61(9): 1039-48.
46. Jackson A, Mead AN, Stephens DN. Behavioural effects of alphaamino- 3-hydroxy-5-methyl-4-isoxazolepropionate-receptor antagonists and their relevance to substance abuse. Pharmacology & therapeutics 2000; 88(1): 59-76.
47. Khazaal Y, Zullino DF. Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms. Journal of clinical psychopharmacology 2009; 29(2): 192-3 author reply 3-4.
48. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clinical neuropharmacology 2005; 28(1): 6-10.
49. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane database of systematic reviews (Online) 2007(3): CD006306.
50. Cohen J, Magalon D, Boyer L, Simon N, Christophe L. Aripiprazole- induced pathological gambling: a report of 3 cases. Current drug safety.; 6(1): 51-3.
51. Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS & neurological disorders drug targets. Mar; 9(1): 50-4.
52. Iancu I, Lowengrub K, Dembinsky Y, Kotler M, Dannon PN. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS drugs 2008; 22(2): 123-38.